Supersaturated Self-Nanoemulsifying Drug Delivery Systems (Super-SNEDDS) Enhance the Bioavailability of the Poorly Water-Soluble Drug Simvastatin in Dogs
暂无分享,去创建一个
Thomas Rades | Anette Müllertz | Nicky Thomas | René Holm | T. Rades | A. Müllertz | R. Holm | N. Thomas | Mats Garmer | Jens Jakob Karlsson | M. Garmer | J. Karlsson | Nicky Thomas
[1] A. Serajuddin,et al. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. , 1991, Journal of pharmaceutical sciences.
[2] Joachim Grevel,et al. Improved Dose Linearity of Cyclosporine Pharmacokinetics from a Microemulsion Formulation , 1994, Pharmaceutical Research.
[3] J. Turgeon,et al. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. , 1998, Trends in pharmacological sciences.
[4] Fang Gao,et al. The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats. , 2010, International journal of pharmaceutics.
[5] A Müllertz,et al. A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[6] T. Rades,et al. Influence of lipid composition and drug load on the In Vitro performance of self-nanoemulsifying drug delivery systems. , 2012, Journal of pharmaceutical sciences.
[7] S. Yuk,et al. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. , 2004, International journal of pharmaceutics.
[8] K. Sako,et al. Timed-release formulation to avoid drug-drug interaction between diltiazem and midazolam. , 2003, Journal of pharmaceutical sciences.
[9] G. Amidon,et al. Pharmacokinetics of the CYP 3A Substrate Simvastatin following Administration of Delayed Versus Immediate Release Oral Dosage Forms , 2008, Pharmaceutical Research.
[10] T. Rades,et al. Precipitation of a poorly soluble model drug during in vitro lipolysis: characterization and dissolution of the precipitate. , 2010, Journal of pharmaceutical sciences.
[11] W. Charman,et al. Lipid-based vehicles for the oral delivery of poorly water soluble drugs , 1997 .
[12] H. Kristensen,et al. A dynamic in vitro lipolysis model. II: Evaluation of the model. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[13] Bradley D Anderson,et al. What determines drug solubility in lipid vehicles: is it predictable? , 2008, Advanced drug delivery reviews.
[14] Ben J. Boyd,et al. Drug Solubilization Behavior During in Vitro Digestion of Simple Triglyceride Lipid Solution Formulations , 2004, Pharmaceutical Research.
[15] D. Hauss. Oral lipid-based formulations. , 2007, Advanced drug delivery reviews.
[16] Terje R Pedersen,et al. Simvastatin: a review , 2004, Expert opinion on pharmacotherapy.
[17] R. Mckinnon,et al. Localization Of Cytochromes P450 In Human Tissues: Implications for chemical toxicity , 1996, Pathology.
[18] Brahmeshwar Mishra,et al. Lipid--an emerging platform for oral delivery of drugs with poor bioavailability. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[19] J. Vermant,et al. Formulate-ability of ten compounds with different physicochemical profiles in SMEDDS. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[20] D. Fatouros,et al. Clinical studies with oral lipid based formulations of poorly soluble compounds , 2007, Therapeutics and clinical risk management.
[21] Yuichi Sugiyama,et al. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. , 2006, Pharmacology & therapeutics.
[22] J. Kovarik,et al. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. , 1994, Journal of pharmaceutical sciences.
[23] R Holm,et al. Supersaturated Self-Nanoemulsifying Drug Delivery Systems (super-SNEDDS) , 2012 .
[24] C. Porter,et al. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs , 2007, Nature Reviews Drug Discovery.
[25] H. Kristensen,et al. Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[26] R. Strickley. Solubilizing Excipients in Oral and Injectable Formulations , 2004, Pharmaceutical Research.
[27] Thierry F. Vandamme,et al. Nano-emulsions and Micro-emulsions: Clarifications of the Critical Differences , 2011, Pharmaceutical Research.
[28] Joachim Grevel,et al. Influence of a Fat-Rich Meal on the Pharmacokinetics of a New Oral Formulation of Cyclosporine in a Crossover Comparison with the Market Formulation , 2004, Pharmaceutical Research.
[29] Christopher J H Porter,et al. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. , 2008, Advanced drug delivery reviews.
[30] A. Fahr,et al. Drug delivery strategies for poorly water-soluble drugs , 2007, Expert opinion on drug delivery.